Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. Using the Myc dominant negative Omomyc, we previously showed that Myc inhibition is a promising strategy for cancer therapy. Here, we preclinically validate Myc inhibition as a therapeutic strategy in mouse and human glioma, using a mouse model of spontaneous multifocal invasive astrocytoma and its derived neuroprogenitors, human glioblastoma cell lines, and patient-derived tumours both in vitro and in orthotopic xenografts. Across all these experimental models we find that Myc inhibition reduces proliferation, increases apoptosis and remarkably, elicits the formation of multinucleated cells that then arrest or die by mitotic catastrophe, revealing a new role for Myc in the proficient division of glioma cells.
Gliomas are the most frequent primary tumours affecting the adult human central nervous system. The World Health Organization defines four brain tumour classes (I, II, III, IV) on the basis of their morphological features and predicted clinical behaviour. The most lethal is grade IV glioblastoma (GBM), with a median survival of only 15 months1,2. However, all grades respond poorly to conventional therapy3. Gliomas are presumed to arise from mature glia or neural stem cells and diffusely infiltrate the surrounding tissue3, making surgical resection very difficult. Gliomas may be astrocytic, oligodendritic or of mixed lineage and are all characterized by refractoriness to apoptosis and marked genomic instability, both of which are thought to contribute to their poor response to chemo- and radiotherapy3. Recurring alterations observed in gliomas include amplification and activating mutations of EGFR, precocious receptor tyrosine kinase signalling, deletion of NF1 and elevated levels of p21ras signalling (reviewed in ref. 3). In particular, signalling through the Ras network is essential for both proliferation4 and angiogenesis5 of human malignant astrocytomas.
Myc is a bHLHZip transcription factor, causally implicated in most human cancers6. Myc controls diverse cellular functions, including cell growth and proliferation, differentiation and programmed cell death. Its expression in normal cells is tightly regulated by mitogen availability but this control is compromised in tumour cells, either as a consequence of constitutive upstream oncogenic signals or direct mutation in the myc genes themselves7. Myc expression correlate with glioma grade8 and some 60–80% of GBM exhibit elevated Myc levels9. In addition, transgenic Myc expression in the astrocytic lineage of mice is sufficient to cause gliomas resembling the human disease10. Increased c-Myc activity downstream of p53 and Pten mutations is also causally associated with impaired neuronal differentiation and enhanced self-renewal capacity of GBM tumour-initiating cells11. Consistently, Myc knockdown in Pten−/−/p53−/− double null neurospheres reduces their tumorigenic potential11. Others have proposed a central role for Myc also in the progression of gliomas driven by various different mutations12,13 suggesting that Myc inhibition could be effective in multiple types of glioma.
To assess the therapeutic potential of Myc inhibition in vivo we previously employed a dominant negative mutant of the Myc dimerization domain, termed Omomyc. Omomyc has an altered dimerization specificity, allowing it to sequester Myc away from its obligate partner Max and so inhibiting Myc-dependent transcriptional activation14,15. Making use of a TRE-Omomyc; CMVrtTA mouse model, in which Omomyc is widely expressed upon doxycycline administration16, we showed that systemic Myc inhibition triggers rapid regression of both KRasG12D-driven lung tumours16,17 and T antigen-driven pancreatic β-cell insulinomas18 in mice. Remarkably, such systemic Myc inhibition elicits only very mild and well-tolerated side effects in normal tissues16. Moreover, we observed no evolution of resistance to Myc inhibition in either tumour model, consistent with the unique and irreplaceable role Myc has as an integrator of proliferative transcriptional programs17.
Here, we perform a comprehensive analysis of the therapeutic impact of systemic Myc inhibition in both progression and maintenance of glioma, comparing for the first time mouse and human experimental models, and investigate its actual mechanism of action.
Myc inhibition increases survival of GFAP-V12Ha-Ras mice
To determine the therapeutic impact of systemic Myc inhibition in both progression and maintenance of glioma, we combined our switchable TRE-Omomyc;CMVrtTA mouse with the well-characterized GFAP-V12Ha-Ras (ref. 19), a spontaneous mouse model of multifocal invasive astrocytoma in which the activated form of Ha-Ras is driven by the glial fibrillary acidic protein promoter (GFAP; Fig. 1a). The molecular and pathological progression of disease in GFAP-V12Ha-Ras mice resembles that of diffuse astrocytomas in humans, exhibiting reproducible kinetics of tumour progression, from astroglial hyperplasia (starting from 1–3 weeks of age) through to low- and high-grade gliomas20.
Omomyc was induced in TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice from postnatal week 8 with doxycycline and the animals then monitored to determine symptom-free survival. Strikingly, at 57 weeks of age, all Omomyc-expressing mice (8/8) were asymptomatic with no evidence of disease progression (Fig. 1b,c). By contrast, at the same time point only 25% of the untreated control GFAP-V12Ha-Ras mice were still alive, the majority having been euthanized by this time point due to the appearance of progressive ataxia and neurological symptoms, associated with astrocytic hyperplasia and increased intracranial pressure (Fig. 1c).
Of note, mice subjected continuously to Myc inhibition showed no sign of any distress or discomfort, confirming the previously reported well-tolerated and mild side effects elicited by Myc inhibition in normal tissue maintenance and homeostasis16.
Myc inhibition limits growth of transformed neuroprogenitors
To understand how Myc inhibition prevents glioma formation, we first investigated the cellular compartment previously identified in different glioma models as the putative cell of origin of the tumour: the neuroprogenitor (NPG) cells21,22. Recent reports demonstrate that glioma cells share features with neural stem and progenitor cells, including a high proliferation rate, and self-renewal and migration abilities3,23,24. As Myc has a demonstrated role in normal and neoplastic stem cell biology, we assessed the impact of Omomyc expression in primary NPG cells derived from our TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice.
Neural progenitor cells were isolated from the subventricular zones (SVZs) of either adult triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras or control double transgenic TRE-Omomyc;CMVrtTA brains and grown as neurospheres in serum-free medium supplemented with growth factors (EGF and bFGF). As expected, the cells stayed strongly positive for GFAP expression (Fig. 2a). In these cultured NPGs, Omomyc mRNA expression was clearly detectable by 48 h of starting doxycycline treatment, whereas no Omomyc signal was detectable in untreated cells (Supplementary Fig. 1). Of note, even though NPG cultures derived from the triple transgenic TRE-Omomyc; CMVrtTA;GFAP-V12Ha-Ras mouse expand significantly more than non-V12Ha-Ras-expressing TRE-Omomyc;CMVrtTA cells, Omomyc expression in Ras-transformed cells profoundly decreased total cell number at 3 days (Fig. 2b). At this same 3-day time point, the control cell culture had barely expanded and Omomyc expression had negligible effect on cell number (Fig. 2c).
To determine the mechanism by which Omomyc expression blocks expansion of NPG cell cultures, we first examined cell death. Omomyc expression induced significant cell death in Ras-transformed NPGs but had no effect on the viability of control TRE-Omomyc;CMVrtTA cells (Fig. 2d,e). Omomyc also profoundly inhibited NPG proliferation: after 3 days of doxycycline treatment, we observed a significant reduction in the percentage of BrdU positive cells in TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras NPGs, down to a rate similar to that observed in TRE-Omomyc;CMVrtTA controls, in which no difference was observed as a consequence of Omomyc expression (Fig. 2f). Hence, Omomyc exerts its effect on Ras-transformed cells both by reducing proliferation and enhancing cell death.
Myc inhibition impairs NPG self-renewal capacity
According to the cancer stem cell hypothesis, the refractoriness of gliomas to eradication by chemo- and radiotherapy is due to a subpopulation of cells within the tumour that has stem cell features, including a high proliferation rate and self-renewal capacity. To investigate whether Myc inhibition impairs these characteristics, we employed a neurosphere self-renewal assay, measuring the number of cells able to reform a secondary neurosphere from a single cell. In this assay, NPGs are seeded at clonal density (500 single cells per well), then cultured with or without doxycycline for 21 days, at which point the number of spheres in each well is determined. Notably, Omomyc expression impairs the self-renewal ability of both the Ras-transformed and the control cells (Fig. 2g and Supplementary Fig. 1b), consistent with the crucial role ascribed to Myc proteins in promoting and maintaining self-renewal and stemness of both neoplastic and normal progenitor cells25,26.
Myc inhibition reverses the symptoms of GFAP-V12Ha-Ras mice
To test the therapeutic utility of Myc inhibition in advanced gliomas, we evaluated the impact of Omomyc expression in TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice presenting already clear neurological symptoms. Due to the variable tumour latency of our colony (see Fig. 1b, untreated–Omomyc animals), such symptoms appeared stochastically: the animals were initially hyperactive and often aggressive, but eventually became almost catatonic and unresponsive to external stimuli. At this point, they were treated with Omomyc. After 7 days of Myc inhibition, the therapeutic effect was dramatic. As documented by the movie (Supplementary Movie 1), mice were typically lethargic at the commencement of treatment, failed to groom and lacked appetite. After 7 days of Myc inhibition however, treated mice were active, responded again to external stimuli and were able to move, eat, drink and groom (Supplementary Movie 2).
Histological analysis of treated versus untreated samples clearly showed that untreated symptomatic mice exhibited regions with high density, GFAP-positive, pleomorphic and infiltrative astrocytes, typical histopathological features of human malignant astrocytomas (Fig. 3, middle versus upper panels). By contrast, the improved health of treated animals was associated with markedly reduced astrocytic (GFAP positive) cell density (Fig. 3, lower panels). Further immunohistochemical analysis of the residual GFAP-positive regions in Myc-inhibited symptomatic mice revealed a significant decrease in the number of proliferating cells compared with untreated mice (3.63% versus 7.83% positivity for the proliferation marker Ki67; Fig. 4a,b). In addition, we noted a small but significant increase in the number of apoptotic (TUNEL-positive) cells in Omomyc-expressing mouse brains when compared with Omomyc-negative controls (1.74% versus 0.48%; Fig. 4a,c), indicating that cell death contributes—at least to some degree—to the reduced cellular density observed upon Myc inhibition. A notable reduction in total cell number after Omomyc expression was confirmed by determining the number of nuclei present in five whole macroscopic fields (see total number of nuclei in treated versus untreated animals in Fig. 4b,c).
Intriguingly, we observed that in the GFAP-positive regions remaining after Omomyc treatment, there was a significant increase in multinucleated GFAP-positive cells compared with untreated animals, suggestive of an effect of Myc inhibition on ploidy and mitosis of astrocytoma cells (Fig. 4d,e).
Myc inhibition triggers mitotic crisis in human GBM cells
To ascertain whether the antitumorigenic effect of Myc inhibition in the mouse model might translate into an analogous therapeutic impact in a human system, we investigated the effect of Omomyc expression in cell lines derived from human grade IV gliomas. U87MG cells27 were infected with retroviruses directing the expression of either GFP (control) or a GFP-Omomyc fusion protein. Consistent with our in vivo results in the GFAP-V12Ha-Ras mouse model, the total U87MG cell number was reduced on Omomyc induction, whereas GFP expression alone had no such effect (Fig. 5a). In addition, we observed a significant increase in cell death in U87MG cells expressing Omomyc, compared with control cells (Fig. 5b). Using a doxycycline-switchable lentiviral vector to drive expression of Omomyc, we also observed an increase in the proportion of flattened, senescent-like cells that stained positively for β-galactosidase (Fig. 5c). Broadly similar observations were made in Omomyc-expressing U373MG cells, which notably are mutant for p53 (Supplementary Fig. 2), although the cell flattening seen in U87MG cultures after Omomyc expression was not recapitulated (Supplementary Fig. 2c).
Cytological examination of fixed Omomyc-expressing U87MG cells stained for tubulin and DNA showed that Omomyc expression causes a reduction in the mitotic index (0.96% versus 1.86% in control cells), but does not affect mitotic progression (the prophase+metaphase/anaphase+telophase ratio was 0.317 in Omomyc-expressing cells and 0.326 in GFP-expressing cells). A fraction of the dividing cells in Omomyc-expressing cultures (14.7%) displayed mitotic defects including multipolar spindles, aberrant chromosome segregation, chromatin bridges in ana-telophase and an irregular central spindle/midbody (Fig. 6a (control cells) versus Fig. 6b (Omomyc-expressing cells)). The final outcome of these defective mitoses was the formation of multinucleated and micronuclei-containing cells (13.6% after 72 h Omomyc expression; Fig. 6c,d, and Supplementary Fig. 3a). Similar results were obtained in U373MG cells with a doxycycline-switchable RFP-Omomyc-expressing vector (Supplementary Fig. 3b and c), where time-lapse imaging over the course of 72 h revealed that multinucleated cells enter mitosis but are unable to complete the mitotic process and may eventually die (Supplementary Movie 3).
Myc inhibition alters SAE1 expression and PTP1B phosphorylation
Loss of SUMO activating enzyme (SAE) expression was recently found to exhibit synthetic lethality together with Myc overexpression28. One intriguing phenotypic outcome of SAE knockdown in Myc overexpressing tumour cells was the appearance of mitotic abnormalities and induction of mitotic catastrophe28. Interestingly, SAE1 is a direct target of Myc29. To verify whether SAE1 could be altered in response to Omomyc expression, we performed western blot analysis on GBM cell lines. We observed a clear reduction of SAE1 expression in U87MG (Fig. 7a). Hence, reduced SAE activity could be responsible for the aberrant nuclei and mitotic catastrophe observed in this cell line.
On the other hand, in U373MG cells we observed no downregulation of SAE1 (Fig. 7a). Instead, phosphorylation of protein tyrosine phosphatase 1B (PTP1B)—a modification associated with and required for cell death during mitotic catastrophe30—was observed in response to Myc inhibition (Fig. 7b), to a degree similar to that caused by Taxol, a well-characterized microtubule stabilizer and mitosis inhibitor previously shown to cause PTP1B phosphorylation30.
These results offer at least two new potential mechanisms for Omomyc-induced cell death in GBM and hint at yet another aspect of proliferative biology in which Myc is involved.
Myc inhibition limits growth of patient-derived tumours
To determine whether the antitumorigenic capacity of Myc inhibition extends to primary human tumour samples and, consequently, might be clinically applicable in human glioma, we used a lentiviral vector to drive doxycycline-dependent Omomyc expression in patient-derived GBM neurosphere cultures derived from a surgically resected human GBM (Supplementary Fig. 4a). In culture, Myc inhibition for 2 weeks reduced the overall number of neurospheres (Fig. 8a) and inhibited self-renewal of spheres after their dissociation (Fig. 8b). No effect of doxycycline treatment was observed in neurospheres lacking the Omomyc lentiviral vector (Supplementary Fig. 4b).
To investigate whether this potentially therapeutic effect might translate into an objective therapeutic impact, disaggregated neurospheres were orthotopically inoculated into the brains of NOD/SCID mice. Animals transplanted with neurospheres harbouring the Omomyc expression cassette were treated continuously with either doxycycline from 3 weeks after transplant (so that Omomyc was expressed throughout tumour development) or with sucrose in control mice. As expected, Myc inhibition significantly potentiated overall survival (Fig. 8c). Importantly, once again, we observed the appearance of aberrant nuclei in nestin-positive cells after Omomyc treatment (Fig. 8d,e).
We previously demonstrated in preclinical mouse models that systemic Myc inhibition is a promising strategy for eradicating lung cancer16,17 and insulinoma18, inducing profound regression of tumours, eliciting only very mild side effects in normal tissues and circumventing the problems with resistance encountered in other targeted therapies. However, whether or not these conclusions were applicable to other types of cancer and to human cancers remained to be established. Here, we extend our previous studies by showing that Myc inhibition has a similar effective therapeutic potential for treating glioma, a disease with an especially dismal prognosis and in urgent need of new therapies. To do this, we made use of several experimental models, encompassing both mouse and human systems, including a Ras-driven mouse model of astrocytoma and NPG cells derived from it, human GBM cell lines and, importantly, a patient-derived neurosphere xenograft model. All these studies, both in vitro and in vivo, indicate that Myc inhibition suppresses glioma formation, inhibits glioma cell proliferation and survival and triggers regression of established disease. Unexpectedly, we also noted that Myc inhibition elicits profound aberrations in glioma cell mitosis, with the appearance of multinucleated cells, micronucleation and also multipolar and disorganised spindles. Time-lapse microscopy confirmed that such aberrant mitotic cells are unable to complete cell division and many subsequently die.
Although the suppression of Myc might be expected to induce replicative arrest—given its intimate role in coordinating cell proliferation—the mechanisms underlying glioma cell mitotic dysfunction and death are particularly intriguing. Interestingly, SUMO pathway components have been shown to be required for cell division and implicated in the control of mitotic chromosome structure, cell cycle progression, kinetochore function and cytokinesis31. Here we show that SAE1, a direct target of Myc29, is downregulated in response to Omomyc expression in U87MG cells (Fig. 7a), suggesting that a reduction in SAE activity is responsible for the aberrant nuclei and mitotic catastrophe observed in this cell line. In contrast, U373MG cells display no such downregulation of SAE1 levels but Myc inhibition is instead associated with the phosphorylation of PTP1B, a modification described to trigger cell death during mitotic catastrophe30. The phosphatase PTP1B has been recently shown to exert antitumour effects in GBM32, however, it displays tumour-promoting effects in other cell types; opposing functions may be controlled by posttranslational modifications and substrate specificity. For example, PTP1B is negatively regulated by sumoylation upon entry into mitosis33, whereas its phosphorylation by Cdk1 and Plk1 during mitotic arrest promotes its activation and tumour suppressing activity30. Details of how these opposing modifications interact to determine cell fate remain unknown.
In this study we provide evidence to support the hypothesis that Myc inhibition blocks protein sumoylation (via decreased SAE1 expression) leading to defective mitosis, and ultimately the induction of mitotic catastrophe. Failure to satisfy the spindle assembly checkpoint (SAC) results in protracted M-phase arrest and sustained activation of mitotic kinases, leading to death during mitosis. In addition, enhanced PTP1B activity as a result of Omomyc-dependent loss of PTP1B sumoylation and consequent gain in its phosphorylation may also directly contribute to mitotic cell death.
Our results demonstrate that Myc holds a central role in proficient mitotic programs, the precise molecular mechanism of which could vary in different cell types depending on the status of other cell cycle or genome integrity regulators, such as p53. It isnot surprising that the pleiotropic nature of Myc is reflected in the degeneracy of its effectors, some of which control programs necessary for efficient cell division.
Whether or not the effects of Myc inhibition on mitotic aberrations are peculiar to GBM cells or also hold in other types of cancer remains to be established. The mode of action of a Myc inhibitor—in our case Omomyc—could vary with the context-specific role of Myc, whose function ramifies throughout all aspects of tumorigenesis both at the intracellular and the extracellular levels. Our data demonstrate that systemic Myc inhibition appears to be a very promising strategy for treating glioma, seemingly irrespective of its driving oncogenic lesions. While direct inhibition of Myc is currently not a pharmacological option, it may in the future prove possible to inhibit Myc function, either directly as recently shown using peptides derived from Myc itself12 or indirectly, as demonstrated for bromodomain inhibitors34.
All the animal studies were performed in accordance with ARRIVE guidelines and following the three R’s rule of Replacement, Reduction and Refinement principles.
Mice were housed and treated in accordance with protocols approved by the Institutional Animal Care and Use Committee at the UCSF (University of California, San Francisco) and by the CEEA (Ethical Committee for the Use of Experimental Animals) at the VHIO (Vall d’Hebron Institute of Oncology), Barcelona.
The anonymized human sample employed was part of the tissue biological material stored in the tumour bank (TB) at the Hospital Vall d’Hebron. The sample had been previously collected with a signed patient consent form and its use had been approved by the Ethics Committee of the Hospital. The sample was a random one among the GBM patient samples available.
Generation and maintenance of mice
TRE -Omomyc;CMVrtTA mice were previously described16. GFAP-V12Ha-Ras (Tg(GFAP-Hras1)1Agu) mice were generated and kindly provided by Dr Abhijit Guha (Toronto Hospital Western Division-UHN) and Dr David H. Gutmann (WUSM) laboratories. The resulting triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice were of a mixed CD1;FVB/N;C57BL/6 background. Doxycycline was dissolved in drinking water (2 mg ml−1 with 5% sucrose) and administered to the animals. Control animals received 5% sucrose.
Tissue preparation and histology
Mouse brains were removed and either frozen in OCT or fixed overnight in Zinc-buffered formalin and processed for paraffin embedding. For histological analysis, tissue sections (5 μm) were stained with haematoxylin and eosin.
For immunohistochemical analysis, tissue sections were de-paraffinized, rehydrated and subjected to high temperature antigen retrieval in 10 mM citrate buffer (pH 6.0). The following primary antibodies were used: rabbit monoclonal anti-Ki67 (clone SP6, Lab Vision, 1:100) rabbit polyclonal anti-GFAP (Novus Biologicals, 1:100), anti-nestin (Millipore, 1:100). These primary antibodies were applied for 2 h in blocking buffer (2.5% BSA, 5% goat serum, 0.3% Triton X-100 in PBS), followed by species-appropriate secondary Alexa Fluor 488 dye conjugated antibodies (Amersham) or Vectastain ABC kit and DAB reagents (Vector Laboratories). Fluorescence antibody-labeled slides were mounted in DAKO fluorescent mounting medium containing 1 μg ml−1 Hoechst counterstain. HRP-conjugated secondary antibodies were visualized by DAB staining (Vector Laboratories). Apoptotic cells were detected with ApopTag Detection kit (Chemicon International). Images were obtained with an Axiovert S100 TV inverted fluorescence microscope (Zeiss) and Open Lab 3.5.1 software, or with an Axiovert 100 inverted microscope (Zeiss) equipped with a Hamamatsu Orca digital camera.
NPG isolation and culture
NPGs were isolated from the SVZ of adult mice. Brains were dissected and washed in Hank’s buffer (Gibco). Tissue samples were minced, digested for 40 min with 0.05% trypsin, triturated and passed through a 45 μm cell strainer (BD Biosciences) to obtain a single-cell suspension. Cells were seeded in serum-free neurobasal medium (Gibco) supplemented with 20 ng ml−1 of Human bFGF (Gibco), 20 ng ml−1 EGF (Sigma), Heparin (Sigma), B27 (Gibco), pen/strep and glutamine. Cells were grown at 37 °C in 5% CO2.
NPG cell growth, Trypan blue exclusion assay and BrdU staining
A total of 105 cells were seeded in triplicate in 12-well plates. They were then counted daily using a Neubauer hemocytometer for 3 days, and cell death was estimated by Trypan blue dye exclusion assay. On the third day, cells were incubated for 5 h with the BrdU substrate (Roche), collected and fixed overnight in 70% ethanol. Staining with the BrdU antibody (BD Biosciences) was performed following the manufacturer’s instructions. Cells were then counterstained with propidium iodide and analysed with a FacsCanto flow cytometer (BD Biosciences). Analysis was performed using FlowJo software.
NPGs were centrifuged with CytoSpin (Eppendorf) to cause them to adhere onto slides and fixed in 4% paraformaldehyde. Fixed cells were blocked with 5% BSA–0.1% Triton and then incubated with rabbit monoclonal anti-Ki67 (clone SP6, Lab Vision, 1:100) and rabbit polyclonal anti-GFAP (Novus Biologicals, 1:500) overnight and counterstained with Hoechst. Images were collected with an Axiovert S100 TV inverted fluorescence microscope (Zeiss) and Open Lab 3.5.1 software.
NPG self-renewal assay
To evaluate the self-renewal capacity of NPGs, a clonal colony-forming assay was used to measure the proportion of cells that were able to make new neurospheres. Single-cell dissociated NPGs were seeded in triplicate into 24- or 96-well plates with 500 cells per well, and the number of newly formed neurospheres was counted after 3–4 weeks.
β-galactosidase staining was performed as described in the protocol (Cell Signaling). GBM cells were incubated for 2 days in the presence of X-gal to visualize the positive blue cells.
RNA and protein analysis
Cells grown and treated or not with doxycycline for 3 days were either used for RNA extraction with a RNAeasy kit (Qiagen) according to manufacturer’s instructions, or lysed in RIPA buffer with proteases and phosphatases inhibitors (Roche). RNA was retro-transcribed with the iScript cDNA Synthesis Kit (Bio-Rad) and quantitative PCR with reverse transcription was performed using the following Taqman probe for Omomyc: 5′-/56- FAM/ATTTCAGAAATGAGCTTTTGCGTCTC /36-TAMSp/-3′. Protein extracts were run on 10% or 12% precast gels (Life Technologies), transferred to PVDF membranes (Millipore) and incubated with antibodies against SAE1 (Novus Biologicals, 1:1,000), PTP1B (BD Biosciences, 1:2,000), FLAG (Sigma, 1:4,000) or actin (Sigma, 1:200,000). Complete western blot images are included as Supplementary Fig. 5.
U87MG and U373MG culture
Human GBM U87MG and U373MG cell lines were maintained in Dulbecco’s Modified Eagle’s medium supplemented with 10% fetal bovine serum, glutamine (2 mM), penicillin (50 units ml−1), and streptomycin (50 g ml−1) at 37 °C in 5% CO2. For growth curves and cell viability assays, 104 cells were seeded in triplicate in 24-well plates. Cells were counted daily using a Neubauer hemocytometer for 5 days, while cell death was quantified by Trypan blue dye exclusion assay.
For the quantification of multinucleated cells, cells were seeded and fixed with 4% paraformaldehyde on coverslips 48, 72 and 120 h after the infection with retroviruses producing either GFP or the fusion protein GFP-Omomyc. Cells were then mounted on microscope slides with 4′,6-diamidino-2-phenylindole (DAPI)-containing Vectashield mounting solution. Images of around 2,000 cells were acquired using a fluorescence microscope (Zeiss) with a × 20 objective. The number of total and GFP+ cells with a number of nuclei >3 were counted.
For mitosis analysis, cells were seeded on coverslips in a six-well plate and fixed 72 h after the infection with retroviruses producing either GFP or the fusion protein GFP-Omomyc. Cells were then permeabilized in PBS containing 0.2% Triton X-100 and blocked in 5% BSA. α-Tubulin was detected using a mouse monoclonal primary antibody (Sigma, T9026, 1:100) and a Cy3 secondary antibody (Jackson ImmunoResearch, 1:10). After immunostaining, cells were mounted on microscope slides with DAPI-containing Vectashield mounting solution (Vector Laboratories). For both Omomyc-expressing and control cells, images of 48 different mitoses were acquired using a fluorescence microscope (Zeiss) with a × 63 objective.
Viral vectors and infections
Omomyc DNA was cloned into the pEGFP retroviral vector (Clontech). A total of 2.5 × 106 293T cells were seeded on 60-mm plates and co-transfected with packaging plasmids Plp1, Plp2, PlpV/SVG (Invitrogen) and pEGFP or pEGFP-Omomyc retroviral constructs using CaPO4 method. Supernatant was collected twice during the 2 days following transfection. The day before transfection, 1.5 × 106 U87MG cells were seeded on 35-mm plates. Cells were then infected with 293T cells-derived supernatant containing retroviruses and polybrene (4 μg ml−1).
Omomyc was cloned into the pTRIPZ lentiviral vector (Open Biosystems, Thermo Scientific) and the shRNA sequences removed. For infections, 293T cells were seeded at 70% confluence and the following morning 25 μM chloroquinone added. Two hours later, 293 cells were transfected with pTRIPZ-Omomyc plus the lentiviral vectors pMD2G and psPAX2 by the CaPO4 method. The medium was changed the following day and sodium butyrate added at 5 mM. Viral supernatants were harvested on the subsequent 2 days, filtered and added to target cells with polybrene (0.8 μg ml−1).
Patient-derived neurosphere culture and orthotopic inoculation
Neurospheres were isolated, cultured and inoculated as described previously35. Briefly, tumour cells from disaggregated patient-derived neurospheres were stereotactically inoculated into the corpus striatum of the right brain hemisphere (1 mm anterior and 1.8 mm lateral to the bregma; 2.5 mm intraparenchymal) of 9-week-old NOD-SCID mice (Charles River Laboratories). Three weeks after transplantation, the animals received doxycycline dissolved in drinking water (2 mg ml−1 with 5% sucrose). Control animals received only sucrose. Mice were euthanized when they presented with neurological symptoms or a significant loss of weight.
Data are shown in bar graphs as means+standard deviation (s.d.), or as standard error (s.e.) if indicated. P-values were calculated using Student’s t-test to compare groups, or log-rank test for Kaplan–Meier curves.
How to cite this article: Annibali, D. et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat. Commun. 5:4632 doi: 10.1038/ncomms5632 (2014).
Kleihues, P., Burger, P. C. & Scheithauer, B. W. The new WHO classification of brain tumours. Brain Pathol. 3, 255–268 (1993).
Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492–507 (2008).
Huse, J. T. & Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319–331 (2010).
Guha, A., Feldkamp, M. M., Lau, N., Boss, G. & Pawson, A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15, 2755–2765 (1997).
Feldkamp, M. M., Lau, N., Rak, J., Kerbel, R. S. & Guha, A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer 81, 118–124 (1999).
Vita, M. & Henriksson, M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 16, 318–330 (2006).
Whitfield, J. R. & Soucek, L. Tumor microenvironment: becoming sick of Myc. Cell. Mol. Life Sci. 69, 931–934 (2012).
Orian, J. M. et al. Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br. J. Cancer 66, 106–112 (1992).
Herms, J. W., von Loewenich, F. D., Behnke, J., Markakis, E. & Kretzschmar, H. A. c-myc oncogene family expression in glioblastoma and survival. Surg. Neurol. 51, 536–542 (1999).
Jensen, N. A. et al. Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. J. Biol. Chem. 278, 8300–8308 (2003).
Zheng, H. et al. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb. Symp. Quant. Biol. 73, 427–437 (2008).
Bidwell, G. L. 3rd et al. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS ONE 8, e55104 (2013).
Hu, Y. H., Kong, S. Q., Kong, H. B., Wu, J. L. & Chen, Z. Targeting c-Myc on cell growth and vascular endothelial growth factor expression in IN500 glioblastoma cells. Chin. Med. J. (Engl) 125, 2025–2031 (2012).
Soucek, L. et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17, 2463–2472 (1998).
Soucek, L. et al. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 62, 3507–3510 (2002).
Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679–683 (2008).
Soucek, L. et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27, 504–513 (2013).
Sodir, N. M. et al. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 25, 907–916 (2011).
Ding, H. et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 61, 3826–3836 (2001).
Shannon, P. et al. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am. J. Pathol. 167, 859–867 (2005).
Alcantara Llaguno, S. et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15, 45–56 (2009).
Assanah, M. et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J. Neurosci. 26, 6781–6790 (2006).
Sanai, N., Alvarez-Buylla, A. & Berger, M. S. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 353, 811–822 (2005).
Westphal, M. & Lamszus, K. Other experimental therapies for glioma. Recent Results Cancer Res. 171, 155–164 (2009).
Kerosuo, L. et al. Myc increases self-renewal in neural progenitor cells through Miz-1. J. Cell Sci. 121, 3941–3950 (2008).
Wang, J. et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 3, e3769 (2008).
Clark, M. J. et al. U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet. 6, e1000832 (2010).
Kessler, J. D. et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348–353 (2012).
Amente, S., Lavadera, M. L., Palo, G. D. & Majello, B. SUMO-activating SAE1 transcription is positively regulated by Myc. Am. J. Cancer Res. 2, 330–334 (2012).
O’Donovan, D. S. et al. Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death. Cell Death Dis. 4, e468 (2013).
Dasso, M. Emerging roles of the SUMO pathway in mitosis. Cell Div. 3, 5 (2008).
Mondol, A. S., Tonks, N. K. & Kamata, T. Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C. Free Radic. Biol. Med. 67, 285–291 (2014).
Yip, S. C., Cotteret, S. & Chernoff, J. Sumoylated protein tyrosine phosphatase 1B localizes to the inner nuclear membrane and regulates the tyrosine phosphorylation of emerin. J. Cell Sci. 125, 310–316 (2012).
Dang, C. V. MYC on the path to cancer. Cell 149, 22–35 (2012).
Anido, J. et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655–668 (2010).
We thank Fanya Rostker for her invaluable assistance with mouse colony maintenance, Nicola Rizzo for technical support and all members of our current and former labs for scientific feedback. We also thank Roderik Kortlever for his assistance with animal care, Ksenya Shchors for help with the GFAP-V12Ha-Ras model, Isabel Huber and Carolina Reventos for help with experiments for the revisions, and Andrea Levi for providing the GFP-Omomyc vectors. This work was supported by grants from the Miguel Servet Program (L.S.), the FERO Foundation (L.S.), the Bear Necessities Pediatric Cancer Foundation (L.S.), Fondazione Guido Berlucchi (S.N.), CNR/MIUR Epigenomic Flagship Project (S.N.), European Research Council grant 205819 (J.S.), Asociación Española contra el Cancer (J.S.), Josef Steiner Cancer Research Foundation (J.S.), Cancer Research UK A12077 (G.I.E.) and the NCI R01 CA98018 (G.I.E.).
The authors declare no competing financial interests.
Supplementary Figures 1-5 (PDF 429 kb)
Video showing symptomatic mouse behavior before treatment with Omomyc. Mice are lethargic, fail to respond to external stimuli, cease grooming and lack appetite. (WMV 3956 kb)
Video showing the improved phenotype of the same mouse after Myc inhibition for 7 days. Animals respond again to external stimuli and eat and groom normally. (WMV 4215 kb)
Cells presenting aberrant nuclei are not able to divide and eventually undergo cell death. U373MG cells were infected with a lentivirus expressing RFP-tagged Omomyc and their fate followed by time-lapse videomicroscopy over the course of 72h. (MOV 16242 kb)
About this article
Cite this article
Annibali, D., Whitfield, J., Favuzzi, E. et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun 5, 4632 (2014). https://doi.org/10.1038/ncomms5632
This article is cited by
Cell Death Discovery (2022)
IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas
Super-enhancer-associated TMEM44-AS1 aggravated glioma progression by forming a positive feedback loop with Myc
Journal of Experimental & Clinical Cancer Research (2021)
Expression and regulatory roles of lncRNAs in G-CIMP-low vs G-CIMP-high Glioma: an in-silico analysis
Journal of Translational Medicine (2021)
Molecular Cancer (2021)